An RNA test in development that confirms whether a patient has HCV within 40 minutes could enable diagnosis and prescribing treatment during a single office visit.
The company said the disposal of these two businesses is part of a strategy to focus entirely on the molecular diagnostics market.
The firm showed 98 percent sensitivity and 100 percent specificity across all major HCV genotypes in a recent study.
The device is expected to be used with Genedrive's hepatitis C virus assay, which recently received CE-IVD marking.
The alliance follows a marketing deal signed with Sysmex Europe that covers Europe, the Middle East, and Africa.
The two companies plan to secure required initial regulatory approvals in individual African territories before expanding to other areas in the region.
The British-based firm says that its assay detects hepatitis C via a single-use, disposable cartridge within 90 minutes of testing.
The researchers found that Cepheid's Xpert HCV viral load assay used at the point of care performed at levels comparable to a laboratory test.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
Despite highly effective HCV drugs, testing for resistance mutations is important to prevent the spread of resistant strains and to tailor treatment.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.